Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nadroparin is a low molecular weight heparin (LMWH) anticoagulant derived from porcine sources. It is used for the prevention and treatment of thromboembolic disorders, including deep vein thrombosis (DVT), pulmonary embolism, unstable angina, and non-Q-wave myocardial infarction. Nadroparin is also indicated to prevent clotting during hemodialysis and in patients undergoing general or orthopedic surgery at risk of thromboembolism. Its mechanism of action involves high-affinity binding to antithrombin III (ATIII), which accelerates the inhibition of factor Xa and, to a lesser extent, factor IIa (thrombin), thereby inhibiting the coagulation cascade. Additional antithrombotic effects include stimulation of tissue factor pathway inhibitor release and activation of fibrinolysis via tissue plasminogen activator from endothelial cells. Developed and manufactured by Sanofi.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nadroparin.